Latest News and Press Releases
Want to stay updated on the latest news?
-
SHANGHAI, China and CUPERTINO, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
SHANGHAI, China and CUPERTINO, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
SHANGHAI, China and CUPERTINO, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
中国上海市与加州库伯提诺市, June 03, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc.（纳斯达克代码：CBMG，以及称为“纳斯达克”或“公司”）是一家临床分期生物制药公司，它从事于癌症有效免疫疗法与退化性疾病干细胞疗法的研究。该公司宣布，公司董事会（“董事会”）已根据1934 年《证券交易法》第 10b5-1 条和第...
-
SHANGHAI, China and CUPERTINO, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
SHANGHAI, China and CUPERTINO, Calif., May 19, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
SHANGHAI, China and CUPERTINO, Calif., May 15, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...
-
Commenced Phase I Trial (CALL-1) for C-CAR011 in adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (ALL) in ChinaStrategic partnership with GE Healthcare Life Sciences...
-
SHANGHAI, China and CUPERTINO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), clinical-stage biopharmaceutical firm engaged in the...